Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH-009 in FGF19-positive previously treated advanced or unresectable hepatocellular carcinoma
CTR20261100Phase 2Active
- Sponsor
- Huahui Health
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HH-009 in hepatocellular carcinoma (HCC), sponsored by Huahui Health. Started May 2026; status: active.
02
Drugs
HH-009
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20261100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261100.